Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic thyroid cancer (ATC) is a highly aggressive malignancy with a poor prognosis.
• Current treatment options for ATC are limited, necessitating the development of novel therapeutic strategies.
• YM155, a small molecule inhibitor, was previously identified as a potential candidate against ATC cell lines.

Purpose of the Study:

• To investigate the therapeutic potential of YM155 in anaplastic thyroid cancer.
• To determine the effects of YM155 on ATC cell survival and identify its underlying mechanisms of action.

Main Methods:

• AlamarBlue assay for cell viability assessment.
• Measurement of phosphorylated γ-H2AX for DNA double-strand breaks.
• Formamidopyrimidine-DNA glycosylase (FPG)-modified alkaline comet assay.
• Reactive oxygen species (ROS) and glutathione (GSH)/glutathione (GSSG) assays.
• Flow cytometry for cell cycle analysis and apoptosis detection.

Main Results:

• YM155 significantly inhibited the proliferation of ATC cell lines.
• YM155 demonstrated a high therapeutic window by sparing normal thyroid cells.
• YM155 induced DNA damage, evidenced by increased γ-H2AX phosphorylation.
• Oxidative stress, indicated by ROS and altered GSH/GSSG levels, contributes to YM155-mediated DNA damage.
• YM155 caused cell cycle arrest at the S phase and G2/M transition, leading to apoptosis.

Conclusions:

• YM155 exhibits potent anti-cancer effects against anaplastic thyroid cancer cells.
• The mechanism involves YM155-induced oxidative stress, DNA damage, cell cycle arrest, and apoptosis.
• YM155 represents a promising therapeutic candidate for anaplastic thyroid cancer, warranting further clinical investigation.